| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.061 | 0.06 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.06 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.086 | 0.06 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.06 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.078 | 0.07 |